All In Biotech

Drug Trial Radar · NCT06742957

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site, Clinical Study to Evaluate the Therapeutic Equivalence of Tapinarof Cream 1% (Teva Pharmaceuticals, Inc.) With VTAMA® Tapinarof (Tapinarof) Cream 1% (Dermavant Sciences, Inc.) in Adult Patients With Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 560 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

560

Actual

Start

Dec 17, 2024

Primary completion

Oct 7, 2025

Study completion Nov 12, 2025

Sponsor

Lead sponsor
Teva Pharmaceuticals USATeva (TEVA)
Sponsor type
Industry
Collaborators
Teva Pharmaceuticals, Inc.
First posted
Dec 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To compare the safety and efficacy of the test (Tapinarof Cream 1%), placebo (vehicle cream) and reference VTAMA® (Tapinarof Cream 1%) treatments to demonstrate clinical equivalence in patients with plaque psoriasis.

Conditions

  • Plaque Type Psorisis

Interventions

  • Tapinarof Cream 1%Drug

    Cream

  • VTAMA®Drug

    Cream

  • PlaceboDrug

    Cream

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary change in the Physician Global Assessment (PGA)Time frame: 12 Weeks

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Site 12107

    Scottsdale, Arizona

  • Site 12101

    Bryant, Arkansas

  • Site 12110

    Dublin, California

  • Site 12112

    Dublin, California

  • Site 12102

    Fremont, California

  • Site 12119

    Huntington Beach, California

  • Site 12120

    Northridge, California

  • Site 12111

    Pomona, California

  • Site 12122

    Greenwich, Connecticut

  • Site 12115

    Fort Lauderdale, Florida

  • Site 12104

    Miami, Florida

  • Site 12116

    Miami, Florida

  • Site 12113

    Miami, Florida

  • Site 12114

    Miramar, Florida

  • Site 12108

    Chicago, Illinois

  • Site 12121

    Rolling Meadows, Illinois

  • Site 12106

    Clarksville, Indiana

  • Site 12123

    Merrillville, Indiana

  • Site 12105

    Louisville, Kentucky

  • Site 12109

    Las Vegas, Nevada

  • 12127

    Woodbury, New York

  • Site 12126

    Portland, Oregon

  • Site 12125

    Upper Saint Clair, Pennsylvania

  • Site 12103

    College Station, Texas

  • Site 12118

    El Paso, Texas

  • Site 12117

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.